Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first ta ...

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled ...

Dry eye often precedes autoimmune disease diagnosis, new study finds

Frequent dry eyes may signal more than simple irritation and could be an early warning sign of an autoimmune disease. This ...
Pharmabiz

Revolo completes patient enrollment in phase 2 trial of ‘1104 in eosinophilic esophagitis

Revolo completes patient enrollment in phase 2 trial of ‘1104 in eosinophilic esophagitis: New Orleans Wednesday, September 14, 2022, 14:30 Hrs [IST] Revolo Biotherapeutics (Rev ...
The Manila Times

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery comp ...
Health.com

Are Your Symptoms From a Cold or COVID?

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...